Clinical Trial: 21239

Trial Status: Open
Disease Type: Lung
Trial ID 21239
Sponsor ID 61186372NSC3002

A Phase 3, Open-Label, Randomized Study of Amivantamab and Lazertinib in Combination with Platinum-Based Chemotherapy Compared with Platinum-Based Chemotherapy in Patients with EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer After Osimertinib Failure

3 Locations

Locations

Arlington Office

Fairfax Office

Gainesville Office

Learn More About This Trial
Other Relevant Trials
Trial ID TAK-981-1502
Sponsor ID Takeda Oncology

Phase 1b/2 Study of TAK-981 Plus Pembrolizumab to Evaluate the Safety, Tolerability, and Antitumor Activity of the Combination in Patients With Select Advanced or Metastatic Solid Tumors

1 Location
Trial ID M20-111
Sponsor ID AbbVie

“A Phase 1 first in human study evaluating safety and efficacy of ABBV-637 as either monotherapy or in combination in adult subjects with relapsed and refractory solid tumors”

1 Location